PLoS ONE (Jan 2021)

Treatment of necrotizing enterocolitis by conditioned medium derived from human amniotic fluid stem cells.

  • Joshua S O'Connell,
  • Bo Li,
  • Andrea Zito,
  • Abdalla Ahmed,
  • Marissa Cadete,
  • Niloofar Ganji,
  • Ethan Lau,
  • Mashriq Alganabi,
  • Nassim Farhat,
  • Carol Lee,
  • Simon Eaton,
  • Robert Mitchell,
  • Steve Ray,
  • Paolo De Coppi,
  • Ketan Patel,
  • Agostino Pierro

DOI
https://doi.org/10.1371/journal.pone.0260522
Journal volume & issue
Vol. 16, no. 12
p. e0260522

Abstract

Read online

PurposeNecrotizing enterocolitis (NEC) is one of the most distressing gastrointestinal emergencies affecting neonates. Amniotic fluid stem cells (AFSC) improve intestinal injury and survival in experimental NEC but are difficult to administer. In this study, we evaluated whether conditioned medium (CM) derived from human AFSC have protective effects.MethodsThree groups of C57BL/6 mice were studied: (i) breast-fed mice as control; (ii) experimental NEC mice receiving PBS; and (iii) experimental NEC mice receiving CM. NEC was induced between post-natal days P5 through P9 via: (A) gavage feeding of hyperosmolar formula four-time a day; (B) 10 minutes hypoxia prior to feeds; and (C) lipopolysaccharide administration on P6 and P7. Intra-peritoneal injections of either PBS or CM were given on P6 and P7. All mice were sacrificed on P9 and terminal ileum were harvested for analyses.ResultsCM treatment increased survival and reduced intestinal damage, decreased mucosal inflammation (IL-6; TNF-α), neutrophil infiltration (MPO), and apoptosis (CC3), and also restored angiogenesis (VEGF) in the ileum. Additionally, CM treated mice had increased levels of epithelial proliferation (Ki67) and stem cell activity (Olfm4; Lgr5) compared to NEC+PBS mice, showing restored intestinal regeneration and recovery during NEC induction. CM proteomic analysis of CM content identified peptides that regulated immune and stem cell activity.ConclusionsCM derived from human AFSC administered in experimental NEC exhibited various benefits including reduced intestinal injury and inflammation, increased enterocyte proliferation, and restored intestinal stem cell activity. This study provides the scientific basis for the use of CM derived from AFSC in neonates with NEC.